TAK-242 in Patients With Acute Alcoholic Hepatitis (NCT04620148) | Clinical Trial Compass
UnknownPhase 2
TAK-242 in Patients With Acute Alcoholic Hepatitis
100 participantsStarted 2021-12
Plain-language summary
A phase 2a double-blind, randomized, placebo-controlled, multicenter, proof-of-concept study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of TAK-242 in subjects with acute decompensation of alcohol-related cirrhosis due to alcoholic hepatitis resulting in acute-on-chronic liver failure.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* History of alcohol-related cirrhosis who continue to drink heavily
* History of an acute decompensating event with a clinical and/or liver biopsy diagnosis of alcoholic hepatitis
* Grade 1 or 2 ACLF using the CLIF-C OF score; OR bilirubin criteria OR criteria of acute kidney injury Stage 1b or 2 after initial supportive treatment with fluids, albumin, or terlipressin; AND CLIF-C ACLF score is \>35 and \<64
* History of alcohol-related cirrhosis based on clinical, radiological, and/or histological evidence
Exclusion Criteria:
* Received certain previous therapies (any investigational drug within 30 days of randomization, corticosteroids for alcohol-induced liver failure within 4 weeks of randomization, or received TAK-242 in any previous study)
* History of liver cirrhosis from other chronic diseases; liver failure from other causes
* History of liver transplantation, post-operative decompensation after partial hepatectomy, acute or subacute liver failure without underlying cirrhosis
* Any untreated infections including gram-positive infections, or active or latent atuberculosis, sepsis or septic shock, or coinfection with hepatitis B virus, hepatitis C virus, hepatitis E virus, or HIV
* Chronic or pre-existing kidney failure, uncontrolled medical disorder that might confound study results or compromise subject safety, oxygen saturation \<90%, or requires mechanical ventilation.
* Uncorrected anemia, methemoglobinemia, disseminated intravascular coagul…
What they're measuring
1
Change in CLIF-C ACLF score from baseline to Day 8